ArriVent BioPharma, Inc. (AVBP) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$16.82

From 52W high−48.36%

Volume1.01M

Market cap$884.58M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$16.82

From 52W high

−48.36%

Volume

1.01M

Market cap

$884.58M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.1x

P/E (TTM)

—

RSI (14)

32.1

MomentumView details →

1D Return

+7.68%

YTD Return

−11.03%

SummaryUpdated Jun 1, 2026

ArriVent BioPharma, Inc. (NASDAQ:AVBP) is a clinical-stage biopharmaceutical company founded in 2021 and headquartered in Newtown Square, Pennsylvania. The company went public in January 2024 and focuses on developing targeted cancer therapies, particularly for non-small-cell lung cancer and other solid tumors. ArriVent operates in the highly specialized field of oncology drug development, with its lead asset being an advanced-stage cancer treatment currently in Phase 3 clinical trials.

Ask drillr about ArriVent BioPharma, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−3.1x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

2.4x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−44.63%

ROA (TTM)

−41.48%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+8.46%

FCF YoY

−16.82%

Revenue CAGR 3Y

—

EPS CAGR 3Y

−68.75%

EBITDA YoY

−13.92%

MomentumView details →

1D Return

+7.68%

YTD Return

−11.03%

1Y Return

−10.46%

RSI (14)

32.1

vs 50D SMA

−33.89%

vs 200D SMA

−33.94%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

14.16x

Quick Ratio

14.16x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.05

EPS Surprise

−6.35%

Beats (12Q)

4/12

Next Q EPS Est

−$1.10

Avg Surprise (4Q)

3.87%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−163.74M

Op. CF (TTM)

−147.93M

Next earningsNov 16, 2026 →

Latest newsMore news →

ArriVent BioPharma, Inc. announced publication in Cell Press of results from the FURTHER Phase 1b study of firmonertinib in EGFR PACC-mutant non-small cell lung cancer.12h ago

Shanghai Allist Pharmaceuticals reported that its ArriVent equity stake had a carrying value of about 302 million yuan as of June 30, 2026, up 67.31% from the end of 2025.12d ago

Similar companies

Theravance Biopharma, Inc.TBPH Jade Biosciences, Inc.JBIO Alto Neuroscience, Inc.ANRO Rigel Pharmaceuticals, Inc.RIGL Odyssey Therapeutics, Inc.ODTX MeiraGTx Holdings plcMGTX Find similar companies →

Latest newsMore news →

ArriVent BioPharma, Inc. announced publication in Cell Press of results from the FURTHER Phase 1b study of firmonertinib in EGFR PACC-mutant non-small cell lung cancer.12h ago Shanghai Allist Pharmaceuticals reported that its ArriVent equity stake had a carrying value of about 302 million yuan as of June 30, 2026, up 67.31% from the end of 2025.12d ago